|
Re: Moderna news
|
4
|
Resverlogix Corp.
|
Aug 12, 2020 10:18AM
|
|
Biotech Showcase January 8-10, 2018
|
4
|
Resverlogix Corp.
|
Dec 15, 2017 11:54AM
|
|
Re: MD&A... Phase 3 European Regulatory Approval
|
4
|
Resverlogix Corp.
|
Jul 27, 2015 07:45PM
|
|
Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694
|
4
|
Zenith Epigenetics
|
Aug 06, 2019 08:37AM
|
|
Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
|
4
|
Resverlogix Corp.
|
Mar 28, 2018 07:29AM
|
|
Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
|
4
|
Resverlogix Corp.
|
Nov 12, 2020 09:46AM
|
|
Re: Futility Analysis - Digging Deeper
|
4
|
Resverlogix Corp.
|
Feb 19, 2016 03:24PM
|
|
Re: MACE event rate
|
4
|
Resverlogix Corp.
|
Nov 03, 2018 04:49PM
|
|
Re: One final thing....
|
4
|
Resverlogix Corp.
|
Jun 01, 2019 12:56PM
|
|
Re: Third Eye, AHA, US Listing
|
4
|
Resverlogix Corp.
|
Sep 11, 2019 04:20PM
|
|
Re: Lilly to Discontinue Development of Evacetrapib
|
4
|
Resverlogix Corp.
|
Oct 12, 2015 04:48PM
|
|
Re: NYAS Symposium ...
|
4
|
Resverlogix Corp.
|
Apr 29, 2016 01:48PM
|
|
Re: Biogen/Eisai Scrap Aducanumab
|
4
|
Resverlogix Corp.
|
Mar 24, 2019 07:49AM
|
|
Re: How should the company be actng just about now,..
|
4
|
Resverlogix Corp.
|
Jun 24, 2019 02:59PM
|
|
Re: Another article
|
4
|
Resverlogix Corp.
|
Nov 20, 2019 02:55PM
|
|
Re: 2019 Potential Events
|
4
|
Resverlogix Corp.
|
Feb 05, 2019 04:54PM
|
|
Re: Will Phase 2a Renal trial start tomorrow?
|
4
|
Resverlogix Corp.
|
Jun 15, 2017 02:38PM
|
|
Re: Zacks SCR Report 6/14/17
|
4
|
Resverlogix Corp.
|
Jun 17, 2017 01:14PM
|
|
Re: Amarin 3 or 5 point MACE
|
4
|
Resverlogix Corp.
|
Feb 13, 2019 09:08AM
|
|
Re: Generic Crestor
|
4
|
Resverlogix Corp.
|
Jul 21, 2016 11:07AM
|
